| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BRIDGEBIO PHARMA | 15 | - | -4,73 % | ||
| INCYTE | 14 | 25 | +0,17 % | ||
| KINIKSA PHARMACEUTICALS | 13 | 11 | +23,40 % | ||
| WAVE LIFE SCIENCES | 9 | 2 | +5,08 % | ||
| AMGEN | 7 | 27 | -0,50 % | ||
| BEONE MEDICINES LTD ADR | 7 | 10 | -1,56 % | ||
| ZAI LAB LTD ADR | 6 | 6 | +1,07 % | ||
| ERASCA | 6 | 2 | -48,36 % | ||
| ACLARIS THERAPEUTICS | 6 | 1 | -1,38 % | ||
| ROCKET PHARMACEUTICALS | 5 | - | -2,68 % |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22:42 | Incyte Welcomes Suky Upadhyay as EVP, CFO | 3 | Contract Pharma | ||
| 22:42 | BofA raises BridgeBio Pharma stock price target on Pfizer settlement clarity | 2 | Investing.com | ||
| 22:24 | Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders | 1 | GlobeNewswire (USA) | ||
| 22:18 | Morgan Stanley raises Incyte stock price target on solid results | 4 | Investing.com | ||
| 22:12 | Trevi Therapeutics, Inc.: Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026 | 1 | GlobeNewswire (USA) | ||
| 22:10 | Incyte: Morgan Stanley hebt Kursziel nach soliden Ergebnissen an | 3 | Investing.com Deutsch | ||
| 22:10 | Galapagos NV: Galapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026 | 177 | GlobeNewswire (Europe) | Mechelen, Belgium; April 28, 2026, 22:01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the Company's Annual and Extraordinary Shareholders' Meetings (AGM... ► Artikel lesen | |
| 22:06 | RBC Capital reiterates Wave Life Sciences stock rating on obesity pipeline progress | 3 | Investing.com | ||
| 22:06 | Design Therapeutics, Inc.: Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates | 2 | GlobeNewswire (USA) | ||
| 21:58 | Wave Life Sciences: RBC Capital sieht über 100 % Kurspotenzial dank Adipositas-Fortschritten | 2 | Investing.com Deutsch | ||
| 21:54 | TD Cowen raises Incyte stock price target to $124 on demand outlook | 2 | Investing.com | ||
| 21:46 | TD Cowen hebt Kursziel für Incyte wegen Nachfrageaussichten auf 124 US-Dollar an | 5 | Investing.com Deutsch | ||
| 21:29 | PTC THERAPEUTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 21:22 | MADRIGAL PHARMACEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 21:16 | Kiniksa Pharmaceuticals International, plc - 10-Q, Quarterly Report | - | SEC Filings | ||
| 21:14 | Design Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 21:10 | BridgeBio: Raymond James bestätigt Kaufempfehlung nach Pfizer-Patentvergleich | 15 | Investing.com Deutsch | ||
| 20:54 | Raymond James reiterates BridgeBio stock rating on Vyndamax settlement | 1 | Investing.com | ||
| 20:42 | Goldman Sachs raises Kiniksa stock price target to $60 on revenue beat | 1 | Investing.com | ||
| 20:42 | Cellares, Cabaletta Bio Ink 10-Year Commercial Supply Pact for Investigational CAR-T Therapy | 2 | Contract Pharma |